open access

Vol 25, No 6 (2020)
Original research articles
Published online: 2020-11-01
Get Citation

Hypofractionated radiation therapy for early breast cancer: Follow up of a new treatment standard

Jose Antonio Solis Campos, Gabriel Antonio Veillon Contreras, Benjamin Tobias Tudela
DOI: 10.1016/j.rpor.2020.08.013
·
Rep Pract Oncol Radiother 2020;25(6):886-889.

open access

Vol 25, No 6 (2020)
Original research articles
Published online: 2020-11-01

Abstract

Aim

To assess the oncological outcomes of patients with early breast cancer treated with breast-conserving surgery and adjuvant hypofractionated radiation therapy.

Methods and Material

This retrospective analysis included all patients ≥50 year of age with T1-2 N0 M0 breast cancer treated at our Radiation Oncology Unit between 2008 and 2011. Whole-breast radiation therapy was delivered to a dose of 42.5 Gy in 16 fractions, without boost. The primary outcome was local control.

Results

212 patients were identified. With a median follow up of 60 months, we found 3% local recurrence and 5.3% regional and/or distant recurrences. At the moment of data analysis, 17 patients had died. Out of 5 local recurrences, 2 had previously had a distant recurrence, both of them died. The other three were still alive at the last follow up. These results are comparable to those observed in Phase III trials that use this fractionation scheme.

Conclusions

The results obtained with this retrospective analysis are comparable to those obtained in large randomized trials. This data also supports the use of hypofractionated radiation therapy in Latin America. Hypofractionated radiation therapy for early breast cancer patients should be the standard adjuvant treatment.

Abstract

Aim

To assess the oncological outcomes of patients with early breast cancer treated with breast-conserving surgery and adjuvant hypofractionated radiation therapy.

Methods and Material

This retrospective analysis included all patients ≥50 year of age with T1-2 N0 M0 breast cancer treated at our Radiation Oncology Unit between 2008 and 2011. Whole-breast radiation therapy was delivered to a dose of 42.5 Gy in 16 fractions, without boost. The primary outcome was local control.

Results

212 patients were identified. With a median follow up of 60 months, we found 3% local recurrence and 5.3% regional and/or distant recurrences. At the moment of data analysis, 17 patients had died. Out of 5 local recurrences, 2 had previously had a distant recurrence, both of them died. The other three were still alive at the last follow up. These results are comparable to those observed in Phase III trials that use this fractionation scheme.

Conclusions

The results obtained with this retrospective analysis are comparable to those obtained in large randomized trials. This data also supports the use of hypofractionated radiation therapy in Latin America. Hypofractionated radiation therapy for early breast cancer patients should be the standard adjuvant treatment.

Get Citation

Keywords

Early breast cancer; hypofrationated whole breast radiation therapy

About this article
Title

Hypofractionated radiation therapy for early breast cancer: Follow up of a new treatment standard

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 25, No 6 (2020)

Pages

886-889

Published online

2020-11-01

DOI

10.1016/j.rpor.2020.08.013

Bibliographic record

Rep Pract Oncol Radiother 2020;25(6):886-889.

Keywords

Early breast cancer
hypofrationated whole breast radiation therapy

Authors

Jose Antonio Solis Campos
Gabriel Antonio Veillon Contreras
Benjamin Tobias Tudela

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl